-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 O7nc43WzYCd7eu6sNM+n7kXhTlQiTnlNTU8fnSfvGWnw9m50qTeQ9/CO3uw+ho5V
 wsQSshEOGfu1ty/1mP6CeA==

<SEC-DOCUMENT>0001193125-09-179829.txt : 20090821
<SEC-HEADER>0001193125-09-179829.hdr.sgml : 20090821
<ACCEPTANCE-DATETIME>20090821163014
ACCESSION NUMBER:		0001193125-09-179829
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20090821
DATE AS OF CHANGE:		20090821
EFFECTIVENESS DATE:		20090821

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-161485
		FILM NUMBER:		091028921

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>ds8.htm
<DESCRIPTION>FORM S-8
<TEXT>
<HTML><HEAD>
<TITLE>Form S-8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>As filed with the Securities and Exchange Commission on August&nbsp;21, 2009 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P> <P
STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM S-8 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>REGISTRATION STATEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B></B><B><I>UNDER</I></B><B> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B></B><B><I>THE SECURITIES ACT OF 1933</I></B><B> </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>ARCA BIOPHARMA, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of Registrant as specified in its charter)
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Broomfield, CO 80021 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Amended and Restated ARCA
biopharma, Inc. 2004 Equity Incentive Plan </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Full title of the plan) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Dr.&nbsp;Michael&nbsp;R. Bristow </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>President and Chief Executive Officer </B>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>Broomfield, CO 80021 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>(Name and address of agent for service) (Telephone number, including area code, of agent for service) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><I>Copies to:
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>John Geschke, Esq. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>Brent D. Fassett, Esq. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>C<SMALL>OOLEY</SMALL> G<SMALL>ODWARD</SMALL> K<SMALL>RONISH</SMALL> <SMALL>LLP</SMALL>
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>380 Interlocken Crescent, Suite 900 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>Broomfield, CO 80021 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(720) 566-4000 </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148;
&#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px;page-break-before:always"></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#120;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CALCULATION OF REGISTRATION
FEE </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="9" VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Title of Securities to be Registered</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Amount<BR>to be<BR>Registered (1)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Proposed<BR>Maximum<BR></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Offering&nbsp;Price<BR>per Share (2)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Proposed<BR>Maximum<BR></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Aggregate<BR></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Offering Price (2)</B>
</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Amount of<BR></B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Registration Fee</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Common Stock (par value $0.001 per share) issuable under the Amended and Restated ARCA biopharma, Inc.
2004 Equity Incentive Plan</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">382,704 shares</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">$3.24</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">$1,239,960.96</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">$69.19</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="9" VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="9" VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), this Registration Statement shall also cover any additional shares of the
Registrant&#146;s Common Stock that become issuable under the plan as set forth herein by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of
outstanding shares of the Registrant&#146;s Common Stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h). The price per share and aggregate offering price are based upon the
average of the high and low prices of Registrant&#146;s Common Stock on August&nbsp;19, 2009 as reported on the NASDAQ Global Market. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXPLANATORY NOTE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 382,704 shares of the Registrant&#146;s Common Stock to be issued pursuant to the Amended and Restated ARCA
biopharma, Inc. 2004 Equity Incentive Plan (the &#147;Plan&#148;). </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>INCORPORATION BY REFERENCE </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Registrant is hereby registering 382,704 additional shares of its Common Stock for issuance under the Plan. The contents of the Registrant&#146;s
Registration Statements on Form S-8 filed May&nbsp;21, 2004 (SEC File No.&nbsp;333-115747),&nbsp;June&nbsp;13, 2006 (SEC File No.&nbsp;333-134981) and September&nbsp;14, 2007 (SEC File No.&nbsp;333-146078) are incorporated by reference herein.
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBITS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;5.1&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Opinion of Cooley Godward Kronish LLP.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">23.1&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consent of KPMG LLP, Independent Registered Public Accounting Firm.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">23.2&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">23.3&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consent of Cooley Godward Kronish LLP is contained in Exhibit&nbsp;5.1 to this Registration Statement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">24.1&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Powers of Attorney are included on the signature page&nbsp;hereto.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan.</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2">
</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Incorporated by reference to the Registrant&#146;s Amendment No. 1 to Quarterly Report on Form 10-Q/A (File No. 000-22873) as filed with the SEC on August 21, 2009.
</FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form&nbsp;S-8 and has duly
caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Broomfield, State of Colorado, on August&nbsp;21, 2009. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA <SMALL>BIOPHARMA</SMALL>, I<SMALL>NC</SMALL>.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;Michael R. Bristow</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Dr. Michael R. Bristow</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>POWER OF ATTORNEY </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>K<SMALL>NOW</SMALL> A<SMALL>LL</SMALL> P<SMALL>ERSONS</SMALL> B<SMALL>Y</SMALL> T<SMALL>HESE</SMALL>
P<SMALL>RESENTS</SMALL></B><SMALL></SMALL>,<B></B> that each person whose signature appears below constitutes and appoints Dr.&nbsp;Michael&nbsp;R. Bristow and Kathryn E. Falberg, and each or any one of them, his true and lawful attorney-in-fact and
agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the
same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every
act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or
his substitutes or substitute, may lawfully do or cause to be done by virtue hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of
1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Signature</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp; Michael R. Bristow</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">M<SMALL>ICHAEL</SMALL> R. B<SMALL>RISTOW</SMALL>, P<SMALL>H</SMALL>.D., M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">President, Chief Executive Officer and Director</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman"
SIZE="2">(Principal Executive Officer)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 21, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;Kathryn E. Falberg</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">K<SMALL>ATHRYN</SMALL> E. F<SMALL>ALBERG</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Chief Financial Officer and Chief Operating Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman"
SIZE="2">(Principal Financial and Accounting Officer)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 21, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;Richard B. Brewer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">R<SMALL>ICHARD</SMALL> B. B<SMALL>REWER</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Chairman of the Board of Directors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 21, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">J<SMALL>EAN</SMALL>-F<SMALL>RAN&Ccedil;OIS</SMALL> F<SMALL>ORMELA</SMALL>, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;J. William Freytag</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">J. W<SMALL>ILLIAM</SMALL> F<SMALL>REYTAG</SMALL>, P<SMALL>H</SMALL>.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 21, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;Linda Grais</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">L<SMALL>INDA</SMALL> G<SMALL>RAIS</SMALL>, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 21, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;Ted W. Love</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">T<SMALL>ED</SMALL> W. L<SMALL>OVE</SMALL>, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 21, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;Mary K. Pendergast</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">M<SMALL>ARY</SMALL> K. P<SMALL>ENDERGAST</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 21, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;Burton E. Sobel</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">B<SMALL>URTON</SMALL> E. S<SMALL>OBEL</SMALL>, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">August 21, 2009</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">J<SMALL>OHN</SMALL> L. Z<SMALL>ABRISKIE</SMALL>, P<SMALL>H</SMALL>.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;5.1&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Opinion of Cooley Godward Kronish LLP.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">23.1&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consent of KPMG LLP, Independent Registered Public Accounting Firm.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">23.2&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">23.3&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Consent of Cooley Godward Kronish LLP is contained in Exhibit&nbsp;5.1 to this Registration Statement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">24.1&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Powers of Attorney are included on the signature page&nbsp;hereto.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan.</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT FACE="Times New Roman" SIZE="2">
</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Incorporated by reference to the Registrant&#146;s Amendment No. 1 to Quarterly Report on Form 10-Q/A (File No. 000-22873) as filed with the SEC on August 21, 2009.
</FONT></P></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>dex51.htm
<DESCRIPTION>OPINION OF COOLEY GODWARD KRONISH LLP.
<TEXT>
<HTML><HEAD>
<TITLE>Opinion of Cooley Godward Kronish LLP.</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 5.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g78205g19c33.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Brent D. Fassett </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">(720) 566-4025
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">fassettbd@cooley.com </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">August&nbsp;21, 2009 </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">ARCA biopharma, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">8001 Arista Place, Suite 200 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Broomfield, CO 80021 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Ladies and Gentlemen: </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">You have requested our opinion with respect to certain matters in connection with the filing by ARCA biopharma, Inc. (the &#147;<B><I>Company</I></B>&#148;) of a
Registration Statement on Form&nbsp;S-8 (the &#147;<B><I>Registration Statement</I></B>&#148;) with the Securities and Exchange Commission covering the offering of up to 382,704 shares of the Company&#146;s Common Stock, $0.001 par value (the
&#147;<B><I>Shares</I></B>&#148;), pursuant to the Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">In connection with this opinion, we have examined and relied upon (a)&nbsp;the Registration Statement and related prospectus, (b)&nbsp;the Company&#146;s Certificate of Incorporation and Bylaws, each as currently in effect, and (c)&nbsp;the
originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the
genuineness and authenticity of all signatures on original documents; the authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity
of certificates of public officials; and the due authorization, execution and delivery of all documents, where authorization, due execution and delivery are prerequisites to the effectiveness of such documents. As to certain factual matters, we have
relied upon a certificate of an officer of the Company and have not independently sought to verify such matters. Our opinion is expressed only with respect to the federal laws of the United States of America and the General Corporation Law of the
State of Delaware. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with
the Plan, the Registration Statement and the related prospectus, will be validly issued, fully paid and nonassessable (except as to shares issued pursuant to certain deferred payment arrangements, which will be fully paid and nonassessable when such
deferred payments are made in full). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">We consent to the filing of this opinion as an exhibit to the Registration Statement. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Very truly yours, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>C<SMALL>OOLEY</SMALL> G<SMALL>ODWARD</SMALL>
K<SMALL>RONISH</SMALL> <SMALL>LLP</SMALL> </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;Brent D. Fassett</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Brent D. Fassett, Partner</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">380 INTERLOCKEN CRESCENT, SUITE 900, BROOMFIELD, CO 80021-8023&nbsp;&nbsp; T: (720)
566-4000&nbsp;&nbsp; F: (720) 566-4099&nbsp;&nbsp; WWW.COOLEY.COM </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>dex231.htm
<DESCRIPTION>CONSENT OF KPMG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.
<TEXT>
<HTML><HEAD>
<TITLE>Consent of KPMG LLP, Independent Registered Public Accounting Firm.</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 23.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We hereby consent to the incorporation by
reference in this Registration Statement on Form&nbsp;S-8 of our report dated March&nbsp;31, 2009, with respect to the balance sheets of ARCA biopharma, Inc. as of December&nbsp;31, 2008 and 2007, and the related statements of operations, preferred
stock and stockholders&#146; deficit, and cash flows for each of the years in the two-year period ended December&nbsp;31, 2008, and for the period from December&nbsp;17, 2001 (inception) to December&nbsp;31, 2008, which report appears in the Form
8-K/A (Amendment No.&nbsp;2), filed March&nbsp;31, 2009, to the Current Report on Form 8-K filed by ARCA biopharma, Inc. on January&nbsp;28, 2009. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>/s/&nbsp;&nbsp;&nbsp;&nbsp;KPMG LLP </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Boulder, CO </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">August&nbsp;19, 2009 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>dex232.htm
<DESCRIPTION>CONSENT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.
<TEXT>
<HTML><HEAD>
<TITLE>Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm.</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 23.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We consent to the incorporation by
reference in this Registration Statement on Form S-8 pertaining to the Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan of our report dated March&nbsp;25, 2009, with respect to the consolidated financial statements of ARCA
biopharma, Inc. (formerly known as Nuvelo, Inc., the entity acquired for accounting purposes by ARCA biopharma, Inc. on January&nbsp;27, 2009), included in the Annual Report (Form 10-K) of ARCA biopharma, Inc. for the year ended December&nbsp;31,
2008, filed with the Securities and Exchange Commission. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>/s/&nbsp;&nbsp;&nbsp;&nbsp;ERNST&nbsp;&amp; YOUNG LLP </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Palo Alto, California </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">August&nbsp;19, 2009 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g78205g19c33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g78205g19c33.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.0"3`P$1``(1`0,1`?_$`+````(#`0$!`0``````
M```````)!@<("@4$`@$``@(#`0$```````````````0#!0$"!@<($```!P`!
M`P,"!`('!P4````!`@,$!08'"``1$A,4"2$5,2(C%C,704)S-;<8.%%A)#96
M&0K1,E)B9!$``@$#`@,#!PD$"@,``````0(#`!$$$@4A,09!<1-188'1(C(4
M\)&AL<'A(Q4'0E(S-/%B<H*R4V,D%PAS-1;_V@`,`P$``A$#$0`_`._CHHJ-
MVRY5*APCJR7:SP%1K[$.[N:LDLPA8M`1`QBD4?2*[=N"AP*/B7R\C#]``1ZU
M9U0:G(`\];*K.VE`2WFK)*GR.<)$GXQIN0=1%<%/3%9*/M*T;Y`;Q[_>$8!2
M)$G?^MZ_CV^O?MTM\=B7MK'T^JF?@,NU]!^CZKWK5E)O]'TF";V?/K=7+I7G
M(^*,Q6)AC-1XJ`4#&1.X8+KD2<$`P>29_%0O](!TRKHXU(05\U+.CQMI<$-Y
MZEW6U:T=%%'111T44=%%'111T44M7AMSCN7)G:]MRVQ42LU>-RPLD:-EH65E
M7SZ6]C<GM9)[YN^130;^HW:@J/IB/8XB'X=(XN6T\KQL``OKM5CEX28T"2JQ
M);U7IE73U5U'111T44=%%'111T44=%%5)NNR57`,HN>M7(Z@PE0BC//8MSD(
M^F9-PJFRAH*.\^Y1?S,JX2;IB("4@J>9ORE,(1S2K#&9'Y"I88FGD$2>\37/
M=DF'\A?E4T28V'9KF_I^,P<PYC8U..3,O'L%$1(J:G9E!/#?;BK1Z"A"2,TZ
M(JH94WY@74\DTJ6.*?<7\64D0CY6'KJ\EF@VQ/!B6\Q'R)/U"F8E^(CAD6#^
MTC7K\=]Z?B-D-H4V$X)_'MZWIE\8`#]_KX^Q]/O_`%>WTZ?_`"W%M:S7\M^-
M5WYGEZKW%O)86JM>,W`'0.(?+:,M-*N4I;\%M53MT9,"NY",EXF8!JW<P+.Y
M0[-1&)L"/JH']G(HI%$BH"0Z20F*92.##?&R0R$F$@_/YZER,Z/*Q=+J!."/
M3Y;>3STTG2=/S['ZG(7G3;;#4RJ1G@5U,33D$$3+J^7H,V:!"J.Y&1<^`@DV
M;IJKJB`^!![=6$DB1+KD("U6I&\C:(P2U+3E/F9XDL)@8UK&:W+LBJBD,VRJ
M,0V9JE`WB"[=E+6>-F5$3!]0\VR:@A_5Z0.Z8P-AJ([JL!M.41?V0?)?[JW;
M@_)O$^2<&YG,BNS*Q#'`B$U!KI.(JSP!U_X19FOR*;>1:)JF`0(L!#MU1`0(
MH;L/9R&>*<7C-_KI*?'FQVTRBWU'TU?0B``(B(``!W$1^@``?B(C_LZFJ&ER
M['\IW$K'YY]6!LL]HTW%KJM)1/-HEM-Q,<\14%-9HO8Y&2AH!RNB8H@<K1PY
M\#!XF[&`0!&7<,:-M-]1\W'Z:?BVW*E758*//ZN=>QAWR:<4]TGF-3BK5+T:
MT2JR;6(B-'BT:\G,/%1$J;*,G&K^5KJ[U4WY4T#NTUE3"!2$,8>W68<_'F;2
M"0Q\M8FV[*@4LPNH[1Q^^F!].TC7/Q\4'^KOE]_9V#_%:6ZIMN_F9?EVU?;G
M_)P^C_#3PM2UK.<4I[^^:C;8JG5:/,1)21E%3`9R[6`WMXZ,9($6?RTFY\!]
M-LV256.!1$"]@$0MI)$B77(0%JDCCDE?1&"6-+9<_,WQ+0EQCDH?7W3(%13^
M\I5"&2;')W[`X28.K4WF3("'U[&;E5[?U._TZ0.Z8P-K-;N^^K$;1EE;^S?R
M7^ZF%XMO63\A*F6Z9)<(^UPQ%B-)!-`J[.6@Y`R0+#&ST,^2;R42]`@]P*LF
M4%"AY)B<O8PO131S+JC((I":&6!]$H(:JG5YMX*SY`I\99:5LL'JJ\TG`-&$
MU5)>/A7L@[C/N\4#.?52^W.&\VT$H,U`-X+JJ%3`?,>W47Q<(F^'-Q)?R?;4
MOP<Y@^)`!BMY>/S5KCIFE:Q_S$YT\=."=0JETY#VF4K\7=K"O6:TS@:])VB:
MDW[.-7E9!=.*BDU7)(V,:)%]PX-V32.LD41\E"@-?N.YXFUQK)EL0K&PL"3R
MN>`[!7>]`?IIU;^IF?/MW2<"2S8T(DD+R+&BJ6"J-3$#4Q)TKS(#$<C47_[A
M>">Q]]]JU[M_E*_SK^U_E1:O>_R*_</[=]_[;VWE^[O4_P",^R?WC]O_`%_3
M\?IU'^;XMKVD_@>-[I]R]OG[;<[<:=_XJZG\3PM>!_[W\HO\3';XWP_$TWO_
M``OV/&_A^)[-[UCOYN;1)QF'Y)66JAB1MCTQ[(RA"B)0<&K-7D5HY!3_`.28
M.9,5>P_UTRC^(!UC=F(B5>PM]0KC-G0&5W[0OUFF2\2Z7"9_QFPJKU]))*/:
MYA3Y`YT@#L\DIZ&:STS)',`?J*R4O)KKF,/U$RG3V,@2!%'[H^FJ_)<R9#LW
M/4:T/U/4%'117.UJ4?/?(K\B$MB4K.2D=AV#KS;:091;GTA!A5G+.+M<BS^A
MD"6&WVIT2/3=F(8[5@F`D#R((&I)`<W-,1/X2?9S]-ZOH].!@"8`&:3[>7H`
M^FG1U[B?QHJ]92I\/A.5D@$VWM#M7U)@9=R[3$G@920E)=D^E)%T</J99=91
M43#W$W?JU7&@5=(1;=PJH;)R&;6SMJ[S21>9V+_]NG=\HY.\=!<UZDV*<=QL
MY2$G3I2)9NVI$I":JA154.HK4[E`D7,DV5.?V3ML)TA*`(@G5947P4ZY$'!"
M>(^SN(JWQ)CGQ-CSV+`<^WO[P:UI\J'*.8JG'G-ZGF$D]8R7))'U_N<<L9M*
MDSLD5%OW[%FJD(+-75F7L#%F8Y#`;VQUR`/<W<&-PR"L`5.<GU6^WE2VVXP;
M(9Y!PC^O[N=7IQ%^/'$<(SRNJW.A5>_:S(Q+-Y;[-;8=C8$8Z4=H)K.8&KQT
MHD[CX:(ASF]`BB297#D2"HJ<?("$FQL**%!J`:2W$D?0*@RLZ:=SI8K%?@!P
M])J#\YOCSQS4LKM]RS.BUV@:W4H20L<,\J,6UK\=:RPS4[YS7)^)BT4(YTI)
MMFYB-G0)%<H.A(;U!3\R&TR\**2,N@"R`=G"I,+/EBE59"6A)L;\;><?+E7L
M?%9R*G]WXZ'B+G(.9>XY+-)TM[,/5#K/YFO+1Z$C5)"174$5%Y!)@=1FJH;N
M=46?J'$3G,/6=OG::&S\64V]5:[E`L$]TX(POZ>VL6?%!_J[Y??V=@_Q6ENE
M=N_F9?EVT]N?\G#Z/\-55S6T"I\C>?T?D&O:6WS?C_CKL(&6DWSX[%HDY;1#
M>;N*S,X)N$D[-99%5*(;N#)F%NBB!@#Z&`T>4ZSYOAR-IA7Y'Y^5;8:-!@F6
M)=4[_(>@<S3#HK0?B2AJ8%!92G&4:P+/V2K5Y#QLB_=$$G@9=Y./XQQ..Y`W
MX^Y4<F<>7Y@.`_7IT/MP71^'II$Q[H6U_B:N_P"R]+0QV[YCQ<^1"IL^-VEQ
M]YP+7Y*"JLDUC)9S)-(ME='JT6VKTLX<%(HZ?TNT>B[8KJ>:WL%P3,<QCJB9
M"-X\?.`@8&%N'S]GH[*L)4DR<`G(73,@OWV[?2.?GK87S`8#)#"T?EG0/<1U
MNS"0AX2WR,:44W:$(,N1[3+7YI%*8%ZG:E2I"H(B/HOBB/8B/36YPFPR$]Y>
M?V?,:5VJ<!FQG]UN7?;B/2*9?Q/WF-Y)8+0=6:F;IRDM&%C;?'-Q#M#W6'[,
M++'>F'U21&03%=N`_46JZ1OP-T]C3">%9.T\^_MJNR83CS-&>0Y=W97+)R;7
M<?+Y\S]/XZP:SF4XX\87<A`W!TT5,>,<UZAS#61VB8*LB==N4]VN:;.J-%P_
MB(HI*!^7OUP>;??^HUQ%XX<%PWDLI]L^EK*#7W[T:J_H+_UXR.KL@"/J[>@K
MQ`CVA),A7$6QL?P82^2R]A)%=@W[3J__`$Y"?\O?M/\`NME_RO\`].?P?[D_
M_+_`_P#KUZ!X:>0<K>CR=U?`OQV;_FR?Q?%]X_Q/\SG[_P#6Y^>L"?*+@LON
M/&"6<U:/5E+=EDTVT6)C6J1EGLI&1[-['6F,9I$[F6<G@)%9RFF`"955J0A0
M$Q@#I3<(3+CW7WE-_74NW3B#)&HV1A8_9]-5K\6?+^J:MCU9PVSSK1CK&81"
M<#%Q[]R1):YT:+3*G`3$**HD!\\AXWP9O6Y/)9,&Y5Q#P4[ETV_)62,1,;2+
M](J3<L1HI3,@_!8_,>W[J;-U8U655TAL^<1NIUW%5;*R<:998B7GVE59'*[D
M&,'"M2.74M-$2,/VAHMZI"-_6\3N#F_3*8I3F+&94$@BO^(>RI!%(8S-;\,&
MUZ1G@EFC^)ORF;;3](72K\#L3ZSLH"P2QRMH_P`;Q865\I3M1ZI^B1I*."JQ
MHJ"8"$>=B'$/$1"IA88^X.LG`->WI-Q5S.OQ.VQM'Q9+7'<+'UUT.]7545(5
M^9#3HR[NL<XPTE1.QZ&]N"-DEH>,$KIW&.Y5@M6*;"N"HB<49.>=3BRP(F[*
M$02(H8`(H01I]SD#Z<=.+WO]@JYVI/#UY$G!+6'UFO&^5['[%1,@XB72.0-)
M-,58L,XG7!`$[5O($AZHO`/'!@[BFTD)*GK("<>Q?453+^)P`<;C$4CC8<0G
M#ZO56^V3!YI4_?X_7?ZZ=CBVN5#=,RJ.H4B2;2,):8EJ],1!8JBT1)BBG]U@
M9),/SM96%?"=NND<`,4Y.X=RB41M8I%EC$B&X(JGEB>&0QN+,#\C4,Y3;75<
M#PS0=`M$@U:G;5V5CJW'+*IE=6&UR3!PU@8..0.8#NG#M\H45`(!O20*HJ;L
M0AA#7(E6&(NWDX><UOC0M/,L:CMX]W;2Z?A6SJ;KF&:/H<JW5;--)O+-&!]4
MATP?1=+C58Q>4;@8``[5>:D7:!3!]#"V-_LZ1VM"L3.>3'AZ*?W:0-,L8_9'
M'O-4G\4'^KOE]_9V#_%:6ZBV[^9E^7;3&Y_R</H_PU2E_P`WR:"^52\5#DW!
M-Y',-5L+R6C',K)RD)%HO+[$-'M2F%92+D(Q=-FE8T%HQ0QE@134,(J?0GTB
M=(QN!2<?AL>[GR^FMXWE;;0V.?Q%'?R/'Z.--\#XQN#H_4,.8B`_4!_>.A=A
M`?P[#^[.K+X#$_=^D^NJK\PS/W_H'JK-2>:?%OFO*2G88TH";#96DC7IFNOH
M^<T.9@XN[)R(/X"M2#U"T/D6=F#VB3L$'*`MBI&*"IRB;P%?P]OCR!$!^+V<
M3:_DY\Z8\3<9,8S%CX)N#RY=IY<NRFR72GU_0:C9J-:V"4I6[=!2==G&"I2B
M5S&2[15D[(43%-Z:H)+"*9P#R3.`&#L(`/5DRJZE&XJ1:JU'9&#K[P-Q7)S(
M<L;[\3\+S7Q.74>N)UY"2$;BKHY#^B34I-%*,HEX32,;P2BY:D2195T8H"'K
M1*2)@[B(ARF9GOL^/.#[Y%D_M'D>ZW'T5[5^E70W_)G76V[6RD[<K^-E6[,>
M+VI%/G=K1+YY`1RK;O\`X\O#UQBO%Z8Y)W>/7+IG*)ZWG8UW)E$TJTR2&6=?
MM(RBBH>X(K<Y1T\FUA'L+A%PT,;N)`'K/2>WG&PCF2W\:?B+\]`Y?/Q/S5WW
M_:[KY.HNM8^D-M<?D^RJ48+[IRG`\7S6B4)"/W2K@<ZZ$.NLKY5HZ**3GRD^
M)VN:):WVJ<=+8ACU]=2!IMU752/6U,=3IU#.%IB"?0@EF:1).'`B<_M4UVPJ
M&$Q$DA$1&LR-N#MXD!TO]'W5:X^YLB>%D#6EK7[;?;6=/\NGS)(MOVBGLKU2
M$``:!-!K<.*@-@#TP.$TO#A=`+X!^/\`%[?[^H/`W/W=7L]X]5ZG\?:;ZM'M
M=Q^J]JUOPB^.2P\>M'7W;6]14O&IO(J8C?M\,9\[AD/OY&Y9%],V.P%&>LTJ
M9-'Q*84VJ:8]Q_4^@@SB8)@D\:1KR6I;,SUGC\&)=,0/RX#E6CN87"',N7U?
M8%L*[BIZ!76ZR%5T"):H.GS)JL<5E8::8+&13G:\LN(J>@91)5%41.BHF)C@
M>?)Q(\E?:X..1^7.E\7,DQ6NO%#S'RY&ES,^$7RBTYDG1:9RUCC4=NF5C'.S
M7RX,UV,:`"1-)ND^JTM,Q944OH"39X8I/P(;L`#TB,3<%&E9?9[SZJ?.9MSG
M6T1U]P]=:MX??&Q5^/MK'7]2MJNQ;6H=PZ:3CU!U]BK4@^*=-]*QA95P\E9J
MQ.$CF)]R>G!0A#F!)),PB86,;`6%O%D.J;R_+M\]+96X-.OA1C1#Y.W^CS4P
MZ_T&HZC3;#G]\A&EBJ-ICEHN;AWI1%%TU5\3%,10@D6;.FRQ"JH+)&(J@L0J
MA#%.4!!YT61"CBZFD$=HW#H;,#PI*<G\8_*+#+-,2O#3DLYK=9F7/K*URR3,
MQ7I%-/R$$$)-6+C)NM6@[-/L4KI=DU7$H``@(]Q&J.!D0D_"R64]AO\`T5;C
M<<:90,N.[#M%C]X^>OKK/Q<;WLEPB;9S6Y$OKS%1"@*)56NS4Y-O7*(G**T<
MC,R[.(BZLR=E+V6-'L3KJ%^A3D-V.&5V^:5@V6^H#L%!W*&%"F''I)[3;[[^
MDT[.KU>O4JN0E1J<.Q@*U7(UI#P<+&(E;L8V-8I%0;-6Z1?P(FF7ZB(B8QNY
MC")A$1M%4(H519150S,[%F-V-+NX9\'KQQGVW;M1LUVJEEB]3))EBXR"9R[=
M_%B^N3VS$]^I()D;J@1LZ!(?3$?U`$?PZ2Q<1X)7D8@AO7>G\O-7(@2)5(*^
MJU6MS+X09YS!KD:68?+5#0ZP@Y1J5\CV:+Y5NU<F!5Q!3T<HHW":K[E</4]+
MU4E6ZHBHD<HF4*I+E8B9*\>#CD?7YJBQ,R3$;AQC/,?;WTN6-X._*)4HTE`J
M?+",1HJ*81[)<F@7)`S&,`#)E1:)NZJ_G(M)-(>P(-G?B3\"F[?7I$8NX+["
MR>QW_<:>.9MSG6T1U]P]8K9?#'XYJ?QCFE]-NED4U/:GZ3PG[H=-54(BM?=`
M,$J:OMWR[R1=RTF50Q7,F[4%RJF8Q"$2*90#LXN"L#>(YU2_0.[UTKEY[Y(\
M-!IB\GE[_53*.GZKZXX/D:B(KY./F,RGAUG+-+]J9(V9U/<+K$CW5<M*^X4M
M^J.'#@GBB52F03LE<9&/^<LT\52$PAX`7S[=S^=;_'MD/\&,V<]W%_F'LCSD
MU]Z?I#CQ?HM^AVX_JINB@;]N<8^$1N>DDIB+;G:675D/;G"BGL-=A4#!P]8@
MX:M5Z.:P\!7HJ.@X2(8I%091<1$LT6$;',T2_E1:L63<B290^A2%`.N_5%10
MB"R`6`\PY5\)9.3D9N3)F9;M)E2NSNS&Y9V)9F)[2222?+7J];5!51[_`&V;
MH&#[9>ZTNDVL=*R/2+;`.7"";I!O-URFS,Q%+K-5@%)RDD^9IF,F8!*<`[#]
M!Z7RI&BQ9)4]]8V([P"15]TM@8VZ]3[=MF8"<3)S\>)P#8E))41@".()4FQ[
M*Q/!P.UX30[AKT#I-_O5`/PCL&@RQM6O;V_OT^15:A4K1#V*&93PKN(**L$(
MY??<6+`6T(!VS<J31$0'RK47)QH6G1W:+X8L=1U'Q`+W%^0(O<"R^05Z)E97
M3G4VZ8^P96'BXVZ#J-($^%A$`.!(YC>-RE@[1N$\-WU369]4C5"*ZYT+*$Y=
MJPV36K>C?OCQO>WRZNAW21M[Z+UZI!5$T+I4G4D)AIP22=X7]>-C0;1)#-6Q
MD&R0ICYQH98+@22-KQ&<ZC>SBW$7Y>]R'#@+`5992;5OC1O+M^#`<7JR##40
M1+$&Q9?%O#*%_BZ?!73))JE.IPSM?A#H9]M%.I<GG-8VS6[2OL7QQ6CD!5I2
M[6UU:[K1-NI3&ELU)&JW1\G^XDX6VKWYL=5@X6=(M7#'R;`D191,8U.1'$84
MDD8R89<$F[*XMR)XV.KD;\N%J?R8NGMPW%-WS-NP8$V_JV+!D6&(10S8<K3'
M3+"OX9>(0,`ZA2RO[>HJ"(O>.6NIR-TY-V*MW&88TNP<%J2IC<8S>&1;0>Y2
M4%1K$XL<$`=P1L+QMR>K)1.7N/:-2[_^WK27/G,DSHQ\,XHT>9[`W'G_`!%^
M:G=MZ$V2';]FP\O'C;<8NIIAE,1<OAJ\T8C?_3!V[(L#_F-Y:OJQ:CI=?^1'
M&J,WOUB5QJJYE7,:OM><OCJQ%FV#6*CK>D5:T3!#@(NK%&0N%(()*F'S*$Z?
MO_%#NRT\R[O'%K/PZH$8=A=@S`GSV2W]ZN8Q-EV?*_2?<-R?%B'4,^8^7!(!
M[4>+C2XN/+&ODC9\TL1R_!'[M4TQU66)N[P:_P`@[S+[*?Y$WF6.L,_FB[L4
M3_E[`6;>S`KBJ[Q\T@JW6ZLLM)EF4F;4S5=$B@N1`_IJ+B=AE>S*QR/BRNC5
M<>'V^QV`#C>W#RUT,NR0-TPOQ>U8T?3PZ3&2,SX81M\=Q,?^[`4O))(!&82[
M:E)&CA<3:O6;3*Q=I':V^O:=+$>_(I8>.EDS:R6MS/YB[RVUWG^7,#'U^J2*
M*Z-/EZ=)R+!^T=QBC8ZOMUD7`+)KB!95>9)3DB1S?+,94FZZ2=(`!Y$&Q!'<
M>=5V5A[/F[<G3K8&$A7I-,^/(CB"9`R8H?B'9Y5(,JRJKHRR!K:E9-)47USS
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M]:=,"'KVO,0)-3,0.B5AU$??V;DS]:.:J-R/#&`5NL1R/*@A21S`V45#`\2@
M0M8/S(U`C4#>W"_;6^X[?@;;N4V[9.VX<.^8_2\>5+C-$/!BS7RH\?5)BGV$
M;P)%E\!UT+(RN8P/9J#ZIJ>V9QAD2%:U&^RSW$_D(MM8&7DYIQ(VN\8=E4!?
MM0D\[O$VJ`O;<W7JD0K'J+NA.Z=IM4#K'46`QS0SSY,.,-#N3%ED7)N2B@MI
M)[>'#CYKU8[)L?3F[]2R?&86+''N72D4FE4"Q0YF2\&,L\*#A$1*X<*ME4LP
M4!;*+P7U/0#H(N&=^L:S9W\GD'GC9PG+*J)K9C(HQKLM,24`1*>IN$W(B5L'
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M!N/?L!>\:9MS%%XH,_QCJ1?CI!DX$<[`6^858YO1G@IN&ZOMC)LPZ1Q)HIO!
M80_$O#@%I$>VCQ69Y;D&Y+/YZU#\AW+6*X3\2=5W5R=LM9XR)"M9E$.A*(3V
MH6@%(VFL!2,`@NU9O3&D'A?Q]@R7-_1T[N^>NVX$F4;:P+*/*QY#[3Y@:XO]
M)^A)_P!1NN\'IA-0PGD\3(8?L8\?M2M?L)7V$_KNM)N_\>OC\RS_`"_3.9>Q
M2R:NM<E$K38*[(3ZAS3@XM3K&"]TOJZB@F4]"\:._,Z<J"'ZB#-FH41*IUSW
M2>((H'W'(/\`N)KD$\]`/%O2W/N%?0/_`&MZKDW7>\/]/>GXR-AV?PDD5!['
MQ<L=HH1;A>''`51V%Y`>(KH9?;7EL;-TVO/;@P1E-`CXJ5J)/;R2K.683SE)
MC`N/NJ+)2*8!.OEB(,2N5T3O%S`FB!S_`)>NL.3`K*A8:G%QSXWY<>7'L\M?
M*4?3N]38V1EQX[&#%=EEXK=60$N-).IM`!+E00@XM8<:M+O_`.O4]4MZJG=Z
M=+Z)A^RY_7_;_?KUE.B4Z$]XK[=I]WL]0F(2-]TN(&!%O[U\3S/V'Q+W'^CJ
M#*C:;%DB3WVC8#O((%7G3&X0;3U)M^ZY5_A<;.@E>PN=,<J.UAVFP-A2LZ7E
M6A:I?M$D('C_`*1C9+G\>=WQ"]3^DHM:ZPM?("13HM>AXW[:WGI-.50JT'%*
MI(SR*`,'C=50&RRI2''JDB@EGE<I$\8;$9&+<+N=(':;V`][D>R]>U;CO>U;
M)MF)'E;IA[@<?JN',A3')D:+!7QI';44729'8$PEM:L!K5215@5:%U?6&TN]
M'#],STM%X`7K`7C718Z*@G]@UZUDJBA:W3D&\L_+8XB++2E`4F$C%C5S/$`;
MJJ_J^G+&L\X)\)TT8C)[0`NYMP''B!IY\N/"JO-R-CV)XX_S+#RSD]4PYH..
MS.J8L7B_B2DJOALWC"T1'B*$;6J^SJF_&&HZ1=-'RN_6_)KEEU,R'AXRX^+M
M-,;P\59;G>[+*YY*VP\57(J9FW+6HUAEG:2`/7AFQW[E^8$$CI(BJ;?"CFDF
MCEDC9(X\?P_:L"6)6]@">`T\SSOPJLZSS]IV[:<[:\#.Q\W<,_?SG`XY=HXH
M(UG6+5(R(#+(9RVA`VA4&HAF"C&="X9[_&YOQ9AYVGR)I6"YQV)KJ38[IB8[
M+C357D1"4^PO#E="5:+EZ[QTIAB)D\E`!ZF!DP[&`*^+;LH0P*ZG4,DZO_&+
M`'NM&GSUZ%NGZ@]+3;OO<^+D+X$O349QC9O:W"4,\J#AP9),_+N3PNAL>5[_
M`+WQKU*P7K6N2:3/5"WJ$YL8K<Z)ET?8F"%0M^4Y2IE6:/;0M6O'P=/7M*4M
M+U!4[M)043)_I@8.QFY<.=Y),RS^*,E"JWX%5TK>W=J/=7+;;U?LN+MF!T>6
MP?RV3IS+BFR6C8RQ9.3\3D",2=@$WPR$!2+WXVY2JOXEIU*TA/<X6A21[3`\
MX=A3EF"!6"<E;>-.^$K58L$VB8K@IWL;6[#%0EF(F<X*@A`K%(F)C`4VZXT\
M<WQ2J=8R7OYXWL"?00&_NTEE=1[/N.T'IK)RD^"EZ;Q2C'45BW#!\22-#P]E
MI(VFQB0+:IU)-A>O"@:'K]CN<CCI<?O<%%,OD(G.2]@U:QMH.-SK^6-:O8:)
M7/VP_"=6F[/9+A*L&+%%HW8`5JFJX6<J)%1*"NJ19#R''\-@!EF0L;:=(;4+
M<;DG@+6X<2>5,Y.Y[!A[>G4'YAC2SMTJFWIC1EVG^(DA^'D\1=`2..)6=RS/
M[1"J@8L=.TN6=`D-,RF'J;&K)W1)7;>.$W-5YPU:/63NL53?LWM%I<2+-\8K
M5U&QE?AW+IPF;R\T43`!3#V*-CGQ&>`1A=7XL9(\PD4GY@+UYWT-N<6S[W)G
M2SG'8;;N")("5(DEP<B.,*5XAF=U53Y2.(YUDIOBVGQ>>TG#3T&5DZKA_/"C
M2E&?*%9/(J4XV*VHVC0$@F+ET(*QF9Q-L/67"1R%5+]C`2IF*8HBB,>=85QM
M!*192Z?(8[Z@?[H.D_V:[MNH=FFW;)ZE&4B9NY=,3+,O$,NX"+X=UX#@V0\0
MR%()!\;B0017RL\_U7&Z)F-92RZYW&F\2.8DQ*U%G4&S*9LEBXTV;/-'CZ1(
MU"',_;N+`MEQ=?;0+M@D!7IFU?64125'P*I@13XT2)H9HX,@VMQ)C*M8@=NG
M4%(Y^R:VDW39.H-TS,QLW&Q]PW[I]%E,I*1IN$<^.TRROI(09/PK3JYNFJ=0
MS+Q(]*J9+H=P@Z).V3,K#"15^YVZIL4W4+$2.1L5:Q^YY=K-,C9"[1S9^Z1B
M7LPE(-#+,BJK.&GW%-)4I52JE)F/'FD57="%?*9R#S",K*+CLOPX=EZCSM]V
MG;\G)Q</-BDGQ>F<;%26/48Y,J')Q9F6%BH+!"K6<@*WALRD@J36&&87O4)B
MF:5F[4.>1M=0^0V"M4J+@\>HJ^RZA.$JE'Z;YIOU2GA)R$@6[XHB;W`E7#R2
M`W<`@QL7*7&1)$.M<L$_V5-M7<0+U<]2]2],9/467F;;DQ'!GZ4>-;:N&3.#
M*V/R]]'=D_=NO`VXU8LJUW&[;-D458\JT-#7<@Y7WR:C]S2K\+&9J/$RQ/K8
MY5@27>*>)-IIG8\_>P\2M`KHFDAL+%%VNC_PA'G4S#*ER(U='^(CG8Z[`+X1
MOPOVW6PT\]0OV7JH@;IO;>G\_(Q,[$.PY^QPH</Q';(_,T6(:S"P)0QSB643
M@^'X#LBM^(8Z]2`Q;16E8Q-->AOT9:O_`"+[!JL\/HQP.X_-IZ]\B)*'MKI8
MK@3&B9"/M,:HGV,97P=I@)`["!<KC2B.(:#J7+9CR]TM)8]W$?/461U%M+YF
MY,,I##+TEBXR<6LV0D.`KQ`6]Y6BD![+J>/E67\PW&_FIS^Y7\?^.5`R*]0W
M%"AS,$M<-D5-#MZFK9[JHB2XW4$5)9.4>M<\HP&9,`]J8YY)T[*0!*<INJ;J
M'#W+=<Z+#BC88*D7?A:YYGR^R.`X<[U['^@'5WZ=_I;T-NO5VZY^-)USDQN(
ML0:S+X<(/A17TE09YO;?VK"-4)X@BG+6?-6^9OZ-G><4"P#0XOBYH6(4TE<A
MSOX>NND/V.A5(F=>("0D0@[C(4X$=+@"2BB9O(X&'Z]%)"(2L4*'PQ`R"PX#
MW;`^3ESKY\PMX?>(<G=MWRHOS.3>H,R7Q'TO(#XQE=`?>(9Q=1Q`(L+5&,ZS
M&PZ):<<EK)&Z+2Z=2<.RIE,U^5AXVO#-Z/E]X:3\5$V!.4CGL^1C"2T6B^1]
M@NU1>E[`HHJE^0=(H'FDC9PZQK$MP0!=E-P#V\#QX6O3>[[QB;5A;ACXCXF1
MN&1N62R.KM)H@R82C-'I8)J=6*'6K%.P*W&F`]6M>74=%%'111T44=%%'111
ET44=%%'111T44=%%'111T44=%%'111T44=%%'111T44=%%?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
